132 related articles for article (PubMed ID: 6788326)
1. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.
Dowd PM; Kovacs IB; Bland CJ; Kirby JD
Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326
[No Abstract] [Full Text] [Related]
2. Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis.
Gaylarde PM
Br Med J (Clin Res Ed); 1981 Dec; 283(6306):1608-9. PubMed ID: 6796187
[No Abstract] [Full Text] [Related]
3. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
[TBL] [Abstract][Full Text] [Related]
4. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome.
Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P
Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252
[No Abstract] [Full Text] [Related]
5. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome.
Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD
Prostaglandins Leukot Med; 1985 Jan; 17(1):1-9. PubMed ID: 3883365
[TBL] [Abstract][Full Text] [Related]
6. Cyclic adenine nucleotide levels in lymphocytes from patients with systemic sclerosis: efficiency of prostaglandin infusions.
Kovacs IB; Dowd PM; Kirby JD; Turner P
Postgrad Med J; 1983 Apr; 59(690):241-3. PubMed ID: 6306626
[TBL] [Abstract][Full Text] [Related]
7. Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.
Martin MF; Tooke JE
Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1688-90. PubMed ID: 6816332
[TBL] [Abstract][Full Text] [Related]
8. Serum from patients with Raynaud's phenomenon inhibits prostacyclin production.
Rustin MH; Bull HA; Machin SJ; Koro O; Dowd PM
J Invest Dermatol; 1987 Dec; 89(6):555-9. PubMed ID: 3316410
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma adrenomedullin concentrations in patients with Raynaud's phenomenon.
Letizia C; Danese C; D'Erasmo E
J Rheumatol; 1999 Mar; 26(3):759-60. PubMed ID: 10090204
[No Abstract] [Full Text] [Related]
10. Assessment of platelet function in patients with Raynaud's syndrome.
Hutton RA; Mikhailidis DP; Bernstein RM; Jeremy JY; Hughes GR; Dandona P
J Clin Pathol; 1984 Feb; 37(2):182-7. PubMed ID: 6229551
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe Raynaud's phenomenon with prostaglandin E1.
Allen JA; O'Reilly MJ
Ir J Med Sci; 1981 Jun; 150(6):190-1. PubMed ID: 7275566
[No Abstract] [Full Text] [Related]
12. Altered behaviour of erythrocytes in scleroderma.
Kovacs IB; Sowemimo-Coker SO; Kirby JD; Turner P
Clin Sci (Lond); 1983 Nov; 65(5):515-9. PubMed ID: 6617097
[TBL] [Abstract][Full Text] [Related]
13. Studies of endogenous catecholamines in patients with Raynaud's phenomenon secondary to progressive systemic sclerosis (scleroderma).
Sapira JD; Rodnan GP; Scheib ET; Klaniecki T; Rizk M
Am J Med; 1972 Mar; 52(3):330-7. PubMed ID: 4551793
[No Abstract] [Full Text] [Related]
14. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous neutrophil activation in patients with primary Raynaud's phenomenon and systemic sclerosis.
Stevens TR; Hall ND; McHugh NJ; Maddison PJ
Br J Rheumatol; 1992 Dec; 31(12):856. PubMed ID: 1458295
[No Abstract] [Full Text] [Related]
16. Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis.
Dörffler-Melly J; Lüscher TF; Wenk M; Wen S; Bollinger A; Franzeck UK
Microvasc Res; 1996 Sep; 52(2):193-7. PubMed ID: 8901448
[No Abstract] [Full Text] [Related]
17. [Rheology of giant capillary occlusion in secondary Raynaud's phenomenon within the scope of systemic sclerosis].
Schmid-Schönbein H; Goebel W; Perkkiö J; Polster H; Jacobs M; Lemmens HA
Vasa Suppl; 1989; 27():61-3. PubMed ID: 2623545
[No Abstract] [Full Text] [Related]
18. Calcium influx into red blood cells: the effect of sera from patients with systemic sclerosis.
Rademaker M; Thomas RH; Kirby JD; Kovacs IB
Clin Exp Rheumatol; 1991; 9(3):247-51. PubMed ID: 1879084
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
20. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon.
Seibold JR; Harris JN
J Rheumatol; 1985 Feb; 12(1):99-103. PubMed ID: 2580093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
